Stock VCYT VERACYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Veracyte, Inc.

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 12:58:32 30/04/2024 am IST 		5-day change 1st Jan Change
20.3 USD +5.13% Intraday chart for Veracyte, Inc. +2.27% -26.21%
15/04 Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating MT
26/02 Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating MT

Business Summary

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Number of employees: 815

Sales per Business

USD in Million2022Weight2023Weight Delta
Diagnostic Products and Biopharmaceutical Services
100.0 %
297 100.0 % 361 100.0 % +21.76%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
92.7 %
263 88.7 % 335 92.7 % +27.23%
International
7.3 %
34 11.3 % 27 7.3 % -21.08%

Managers

Managers TitleAgeSince
Marc Stapley CEO
 Chief Executive Officer 54 01/21/01
Rebecca Chambers DFI
 Director of Finance/CFO 46 19/21/19
Steven French CTO
 Chief Tech/Sci/R&D Officer - 01/22/01
Phillip Febbo CTO
 Chief Tech/Sci/R&D Officer 57 02/23/02
Richard T. Kloos CTO
 Chief Tech/Sci/R&D Officer - 05/12/05
Shayla Gorman IRC
 Investor Relations Contact - 01/22/01
Tracy Morris IRO
 Public Communications Contact - -
John Leite PRN
 Corporate Officer/Principal - 01/22/01
Annie McGuire HRO
 Human Resources Officer 44 28/22/28
Robert Brainin PRN
 Corporate Officer/Principal 53 08/21/08

Members of the board

Members of the board TitleAgeSince
Evan Jones BRD
 Director/Board Member 67 01/08/01
Robert Epstein CHM
 Chairman 69 12/15/12
Karin Eastham BRD
 Director/Board Member 74 01/12/01
John Bishop BRD
 Director/Board Member 79 01/14/01
Jens Holstein BRD
 Director/Board Member 60 01/20/01
Marc Stapley CEO
 Chief Executive Officer 54 01/21/01
Eliav Barr BRD
 Director/Board Member - 09/22/09
Muna Bhanji BRD
 Director/Board Member 61 19/21/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,436,369 77,537,934 ( 98.85 %) 0 98.85 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.482 %
7,118,211 9.482 % 158 M $
Wellington Management Co. LLP
9.416 %
7,068,435 9.416 % 157 M $
ARK Investment Management LLC
9.382 %
7,042,783 9.382 % 156 M $
BlackRock Advisors LLC
8.814 %
6,616,546 8.814 % 147 M $
Dimensional Fund Advisors LP
4.493 %
3,372,703 4.493 % 75 M $
SUMITOMO MITSUI TRUST HOLDINGS, INC.
4.459 %
3,347,436 4.459 % 74 M $
Artisan Partners Holdings LP
4.286 %
3,217,728 4.286 % 71 M $
STATE STREET CORPORATION
4.141 %
3,108,639 4.141 % 69 M $
Nikko Asset Management Americas, Inc.
4.136 %
3,104,676 4.136 % 69 M $
ArrowMark Colorado Holdings LLC
3.353 %
2,517,140 3.353 % 56 M $

Company contact information

Veracyte, Inc.

6000 Shoreline Court Suite 300

94080, South San Francisco

+650 243 6300

http://www.veracyte.com
address Veracyte, Inc.(VCYT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Diagnostics & Testing

Sales per region

Ratings for Veracyte, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
19.31 USD
Average target price
30.83 USD
Spread / Average Target
+59.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
VERACYTE, INC. Stock Veracyte, Inc.
-26.21% 1.48B
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.42% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+47.11% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-33.20% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.15% 2.08B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+19.47% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 733M
CAREDX, INC Stock CareDx, Inc
-31.33% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-43.78% 383M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+29.03% 332M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. VCYT Stock
  4. Company Veracyte, Inc.